Allarity Therapeutics(US:ALLR) GlobeNewswire News Room·2024-11-05 21:15Core Viewpoint - Rosen Law Firm is reminding investors who purchased Allarity Therapeutics, Inc. securities during the specified Class Period of the upcoming lead plaintiff deadline on November 12, 2024 [1]. Group 1: Class Action Details - Investors who bought Allarity securities between May 17, 2022, and July 19, 2024, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties can join by submitting a form or contacting the law firm [3][6]. - To serve as lead plaintiff, individuals must file a motion with the Court by November 12, 2024 [3]. Group 2: Law Firm Credentials - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions, highlighting its own achievements, including the largest securities class action settlement against a Chinese company at the time [4]. - The firm has been ranked No. 1 for securities class action settlements in 2017 and has consistently ranked in the top 4 since 2013, recovering hundreds of millions of dollars for investors [4]. Group 3: Case Allegations - The lawsuit alleges that Allarity and its former officers made false and misleading statements regarding the regulatory prospects of their drug candidate Dovitinib, which treats renal cell carcinoma [5]. - It is claimed that the defendants engaged in improper conduct related to the Dovitinib new drug application and premarket approval application, leading to increased regulatory scrutiny and potential legal repercussions [5]. - Following the announcement of an investigation into Allarity's conduct, the company allegedly downplayed the likelihood of enforcement actions, resulting in materially false public statements [5].